NGR 5172 Deliverable 6 Evidence-Based Guidelines for Medication Administration

Need Help Writing an Essay?

Tell us about your assignment and we will find the best writer for your paper

Write My Essay For Me

NGR 5172 Deliverable 6 Evidence-Based Guidelines for Medication Administration

Order ready-to-submit essays. No Plagiarism Guarantee!

Note:  All our papers are written from scratch by human writers to ensure authenticity and originality.

Student Name

Rasmussen University

NGR5172

Professor Name

Date

Safe and Effective Administration of Hematologic, Immunologic, and Oncologic Agents Across the Lifespan

With the opening of a new oncology unit, the organization can utilize the opportunity to create a culture of high-quality and safety of high-risk medication administration. This bedside handbook aims to help train the staff nurses to administer hematologic, immunologic, and oncologic pharmacologic agents with accuracy, safety, and evidence-driven practices as a newly hired MSN-prepared nurse.

Although life-saving, these drugs are associated with serious risks such as cytotoxicity, immunosuppression, and serious adverse effects (Friganović et al., 2022). Hence, the nurses need to be effective in calculating dosage, patient monitoring, precaution handling, and interprofessional communication to achieve the best patient outcomes throughout their lifespan, both pediatric and geriatric groups.

Hematologic Pharmacologic Agents Across the Lifespan

Hematologic medications refer to the drugs that are employed to treat disorders that involve blood that including anemia, thrombocytopenia, and clotting abnormalities. The most frequently used are the erythropoiesis-stimulating agents (ESAs), iron supplements, anticoagulants, and antiplatelet medications (Oyuku & Nshakira, 2025). The American Society of Hematology recommends that the administration of these drugs be done in individual doses depending on renal diseases, weight, and comorbidities.

Indicatively, erythropoietin (epoetin alfa) and darbepoetin alfa are to be used subcutaneously or intravenously under strict control of hemoglobin levels, whereby it should not be allowed to go beyond 11 g/dL of blood to minimize chances of thromboembolic events. Doses are computed using weights in pediatric patients, whereas continuous monitoring of hematocrit is imperative. Oral or intravenous iron replacement therapy should be age-specific tolerance and absorption variations, with hypersensitivity reactions being observed during IV infusion.

In adults under anticoagulant therapy with heparin or warfarin, a nurse should monitor the INR or aPTT periodically and evaluate the baseline coagulation tests. Among elderly patients, the dosing should be determined based on the renal and fall risks to avoid hemorrhage. Nurses should inform every patient on bleeding precautions, diet interaction, and the need to adhere to them (Hong, 2025). With the opening of a new oncology unit, the organization can utilize the opportunity to create a culture of high quality and safety of high-risk medications.

This bedside handbook aims to help train the staff nurses to administer hematologic, immunologic, and oncologic pharmacologic agents with accuracy, safety, and evidence-driven practices as a newly hired MSN-prepared nurse. Although life-saving, these drugs are associated with serious risks such as cytotoxicity, immunosuppression, and serious adverse effects (Nouri et al., 2021). Hence, the nurses need to be effective in calculating dosage, patient monitoring, precaution handling, and interprofessional communication to achieve the best patient outcomes throughout their lifespan, both pediatric and geriatric groups.

Immunologic Pharmacologic Agents Across the Lifespan

Hematologic medications refer to the drugs that are employed to treat disorders that involve blood that including anemia, thrombocytopenia, and clotting abnormalities. The most frequently used are the erythropoiesis-stimulating agents (ESAs), iron supplements, anticoagulants, and antiplatelet medications (Thubab, 2025). The American Society of Hematology recommends that the administration of these drugs be done in individual doses depending on renal diseases, weight, and comorbidities. Indicatively, erythropoietin (epoetin alfa) and darbepoetin alfa are to be used subcutaneously or intravenously under strict control of hemoglobin levels, whereby it should not be allowed to go beyond 11 g/dL of blood to minimize chances of thromboembolic events.

Doses are computed using weights in pediatric patients, whereas continuous monitoring of hematocrit is imperative. Oral or intravenous iron replacement therapy should be age-specific tolerance and absorption variations, with hypersensitivity reactions being observed during IV infusion (Oyuku & Nshakira, 2025). In adults under anticoagulant therapy with heparin or warfarin, a nurse should monitor the INR or aPTT periodically and evaluate the baseline coagulation tests. Among elderly patients, the dosing should be determined based on the renal and fall risks to avoid hemorrhage. Nurses should inform every patient on bleeding precautions, diet interaction, and the need to adhere to them.

Oncologic Pharmacologic Agents Across the Lifespan

The greatest nursing attention is required for oncologic agents, such as chemotherapeutic agents, targeted therapies, and biologic agents. To avoid occupational exposure, safe handling measures laid down by the Oncology Nursing Society (ONS) and OSHA should be adhered to in the letter. These involve the use of proper PPE, transfer devices that use closed systems, and the disposal of cytotoxic waste in special containers.

Drugs like cisplatin, doxorubicin, and cyclophosphamide, chemotherapeutic agents, necessitate assessment of complete blood counts, liver, and renal functioning before administration (Friganović et al., 2022). Some of the contraindications and toxicities that should be assessed by the nurses include myelosuppression, cardiotoxicity, and nephrotoxicity. In pediatric cases, the dosing should be weight or surface-area-adjusted, and the growth and the developmental impact should be monitored long-term.

Specific cancer-targeting therapies and immunomodulatory drugs such as monoclonal antibodies (e.g., rituximab, pembrolizumab) require close monitoring during the infusion in the case of anaphylaxis or cytokine-release syndrome (Hong, 2025). Antihistamines or corticosteroids premedication can be necessary. A geriatric patient with several comorbidities ought to undergo a polypharmacy evaluation and organ functioning before the beginning of therapy. Infusion rates, patient tolerance, and adverse effects should be recorded carefully by the nurses.

Education of the patient is a key element in the pharmacotherapy of cancer (Friganović et al., 2022). Patients and families are to be instructed about the signs of infection, treatment of nausea, treatment schedules, hydration, and nutrition. Multidisciplinary collaboration among pharmacists and oncologists improves medication safety and compliance with evidence-based treatment.

Conclusion

Hematologic, immunologic, and oncologic agent administration entails a solid pharmacology understanding, adherence to evidence-based practice, and synergy among the healthcare team. Being nurses working on this new oncology unit, it will be necessary to remain competent in working with high-alert drugs, identifying the initial symptoms of adverse reactions, and implementing the latest clinical standards to ensure better patient outcomes and safety. This handbook is a fast reference and educational guide used to help excellence in oncology nursing practice.

Struggling with NGR 5172 Deliverable 6 Evidence-Based Guidelines for Medication Administration? Get expert assistance from Writink Services!

References for NGR 5172 Deliverable 6

Friganović, A., Mędrzycka-Dąbrowska, W., Krupa, S., Oomen, B., Decock, N., & Stievano, A. (2022). Nurses’ knowledge and attitudes towards biosimilar medicines as part of evidence-based nursing practice: international pilot study within the project Biosimilars Nurses Guide version 2.0. International Journal of Environmental Research and Public Health, 19(16), 10311. https://doi.org/10.3390/ijerph191610311

Hong, J. (2025). Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes. Blood Research, 60(1), 52. https://doi.org/10.1007/s44313-025-00099-x

Nouri, A., Seyed Javadi, M., Iranijam, E., & Aghamohammadi, M. (2021). Improving nurses’ performance in the safe handling of antineoplastic agents: a quasi-experimental study. BMC Nursing, 20(1), 247. https://doi.org/10.1186/s12912-021-00771-4

Oyuku, M., & Nshakira, N. (2025). Factors influencing compliance with chemotherapy handling and administration standard operation procedures among nurses and pharmacists at Uganda Cancer Institute: descriptive study. BMC Health Services Research, 25(1), 1010. https://doi.org/10.1186/s12913-025-13076-y

Thubab, R. Y. (2025). View of precision pharmacy in hematology: Integration of pharmacogenomics into clinical decision-making in anticoagulant and chemotherapeutic agents. Saudijmph.com, 2(2), 212–224. https://saudijmph.com/index.php/pub/article/view/81/59

Related Sample for NGR 5172

NGR 5172 Deliverable 1, NGR 5172 Deliverable 2, NGR 5172 Deliverable 3, NGR 5172 Deliverable 4, NGR 5172 Deliverable 5

Frequently Asked Questions

Question 1: Where can I find sample paper for NGR 5172 Deliverable 6?

Answer 1: You can find free sample paper for NGR 5172 Deliverable 6 from Writink Services website.

Question 2: How can I get help completing NGR 5172 Deliverable 6?

Answer 2: Contact Writink Services to get help completing your NGR 5172 Deliverable 6.